Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359194 | 0.79 | LMNA (0.41) | HTTLMNAP2RX7GAAPOLB | |
| SCHEMBL1032275 | 0.76 | SMN1; SMN2 (0.53) | LMNAALDH1A1POLBTDP1SMN1; SMN2 | |
| SCHEMBL1719924 | 0.75 | LMNA (0.47) | HTTLMNAP2RX7ALDH1A1 | |
| SCHEMBL11714467 | 0.74 | HSP90AB1 (0.44) | HTTLMNAP2RX7PKMALDH1A1 | |
| SCHEMBL5094342 | 0.74 | P2RX7 (0.41) | HTTLMNAP2RX7PKMGAA | |
| SCHEMBL536418 | 0.74 | P2RX7 (0.35) | HTTLMNAP2RX7PKMPLK1 | |
| SCHEMBL17033024 | 0.74 | ANO1 (0.43) | HTTLMNAPOLB | |
| SCHEMBL8570752 | 0.74 | P2RX7 (0.47) | HTTLMNAP2RX7PKMGAA | |
| SCHEMBL8572812 | 0.74 | KEAP1 (0.44) | HTTP2RX7PKMALDH1A1SMN1; SMN2 | |
| SCHEMBL30193187 | 0.72 | LMNA (0.50) | HTTLMNAP2RX7GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431556-B2 | C-21-keto lupane derivatives preparation and use thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | MOINET CHRISTOPHE | 2011-03-31 | — | — | US | disclosed |
| US-7666869-B2 | to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]:** Image-1wherein symbols in the formula have the following meanings;A: CH2 or S , antidiabetic agents | MITSUBISHI TANABE PHARMA CORP. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077228-A1 | NOVEL C-21-KETO LUPANE DERIVATIVES PREPARATION AND USE THEREOF | CYP51A1, CYP17A1, HSD17B7 | HTT 4613/4885LMNA 586/4885P2RX7 3887/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | HTT 1701/4885LMNA 3030/4885P2RX7 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.